JDNPPA

JDNPPA has been a member of Linktree for 1 year and joined in June 2025. The social media accounts linked to from JDNPPA are: • Facebook • Instagram • YouTube • X Besides social media accounts, JDNPPA has populated their site with: • JDNPPA • June 2026 • Page 31 • Alpha-gal Syndrome on the Rise: What to Tell Your Concerned Patients • JDNPPA • April 2026 • Page 22 • JDNPPA • April 2026 • Page 27 • JDNPPA • April 2026 • Page 14 • JDNPPA • April 2026 • Page 17 • JDNPPA • April 2026 • Page 18 • Ask the Expert: Navigating the Latest Cosmetic Trends in Clinical Practice • JDNPPA • April 2026 • Page 12 • JDNPPA • April 2026 Castle Biosciences Supplement • AAD's First-ever Pediatric Eczema Guidelines: Here's What to Know • JDNPPA • April 2026 • DermVIP 2026 Summit Registration Form • Case Study: Clinical Improvement of Refractory Red Scrotum Syndrome With Topical Ruxolitinib 1.5% Cream • Tralokinumab Delivers Sustained Clearance in AD Patients With Darker Skin Tones and Hand and/or Foot Involvement • Grand Rounds: Atopic Dermatitis • JDNPPA • February/March 2026 • Page 32 • CDNPPA Dermatology Essentials for NPs and PAs • Diversifying Professional Experience: How Leadership Roles, Publishing, Podium Speaking, and Collaborating With Industry Can Fortify a Dermatology APP Career • JDNPPA • February/March 2026 • Page 24 • JDNPPA • February/March 2026 • Page 10 • JDNPPA • February/March 2026 • Page 28 • JDNPPA • February/March 2026 • Page 44 • JDNPPA • November/December 2025 Castle Supplement • JDNPPA • October/November 2025 • Page 36 • JDNPPA • October/November 2025 • Page 34 • JDNPPA • October/November 2025 • Page 38 • JDNPPA October/November 2025 Page 30 • JDNPPA October/November 2025 Page 28 • Prescribing Hope: Exploring What's Possible with Topical JAK Inhibition in Atopic Dermatitis • JDNPPA October/November 2025 Page 25 • JDNPPA Takes a Look Back at the Biggest Dermatology News of 2025 • JDNPPA October/November 2025 Page 17 • JDNPPA November/December 2025 Castle Innovations Supplement • Grand Rounds Psoriasis: WWYD? • Grand Rounds Acne: WWYD? • The Dermatology Digest • LEO 2026 Evidence Review • • JDNPPA October/November 2025 Page 38 • JDNPPA • June 2026 • Page 16 • Treating Seborrheic Dermatitis November/December 2025 • News Your Patients Can Use: National Eczema Association Launches Free "Living Well With Eczema" Events • JDNPPA October/November 2025 • Grand Rounds: Acne • JDNPPA September/October 2025 Page 12 • JDNPPA • June 2026 • Page 14 • Grand Rounds: Seborrheic Dermatitis. What Would You Do? - JDNPPA • JDNPPA August/September 2025 Arcutis Supplement • JDNPPA • June 2026 • Beiersdorf On-Demand • Spotlight on HS With Dr. Martina Porter • Previewing 2026 Maui Derm Summer NP+PA • JDNPPA September/October 2025 • Register • JDNPPA September/October 2025 Page 31 • Prescribing Hope in Vitiligo • Understanding the Role of Type 2 Inflammation in Itch Across Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria • The Dermatology Digest • May/June 2026 • Fall Clinical 2025 News: PsO Patients, Providers Would Prefer Pill Over Injectables, Topicals • JDNPPA September/October 2025 Page 10 • JDNPPA June/July 2025 • The Blend Podcast • JDNPPA April/May 2025 Page 47 • JDNPPA February/March 2025 Page 22 • Putting Patients First: Pearls on Improving Access to PsO Medications - JDNPPA • Turning Points in Treating Vitiligo: The Patient Journey • JDNPPA September/October 2025 Page 24 • The Role of Mindfulness Meditation in Dermatology: Enhancing Patient Care and Provider Well-Being • Cemiplimab Approved to Treat cSCC With High Risk of Recurrence After Surgery and Radiation • JDNPPA September/October 2025 Page 36 • The Dermatology Digest November/December 2025 Castle Innovations Supplement • Prescribing Hope: Exploring What's Possible with Topical JAK Inhibition in Vitiligo • U.S, FDA Approves Ruxolitinib Cream 1.5% (Opzelura, Incyte) for Kids Age 2 and Older with AD • Grand Rounds: Atopic Dermatitis. What Would You Do? • JDNPPA June/July 2025 Vitiligo Supplement • JDNPPA June/July 2025 Castle Supplement • Hot Takes from DERM2025 With Joe Gorelick, MSN, FNP-C • U.S. FDA Warns Mousse Sunscreen Makers: Here's What Your Patients Should Know • Key Takeaways From the Second Annual UCB HS Summit With Dr. Steve Daveluy • Diagnosing GPP Early: Here's What to Know and Do • Cyst Mimicry: A Case of Cutaneous Metastasis in a 74-year-old Woman • Pro Pointers on Helping Patients With Inflammatory Skin Diseases Look and Feel Their Best • Scratching the Surface: Managing Itchy Skin During Pregnancy • How Leadership Roles, Publishing, Podium Speaking, and Collaborating With Industry Can Fortify a Dermatology APP Career • On the Road With Project Happy Face and Amy Snow, PA-C • Catching Immune Drift: A Guide for Dermatology APPs • BULLOUS PEMPHIGOID: A Review of the Diagnosis, Management, and Monitoring • JDNPPA Supplements of 2025 • Let's Talk About Acne • What Will the U.S. FDA Nod for Delgocitinib Cream (Anzupgo) Mean for Your CHE Patients? - JDNPPA • U.S. FDA Approves Delgocitinib Cream (Anzupgo, LEO Pharma) for Chronic Hand Eczema: What to Know - JDNPPA • JDNPPA June/July 2025 Page 52 • Taking a Closer Look at Bullous Pemphigoid • Enhancing Patient Care and Provider Well-Being • Confronting Misconceptions about Sunscreen Safety • Diagnosing and Treating Bullous Pemphigoid (BP): A Conversation With Margaret Bobonich and Dr. Donna Culton